| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 09/18/2003 | US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer |
| 09/18/2003 | US20030175881 Nucleic acids encoding (poly) peptides having chips activity |
| 09/18/2003 | US20030175805 Comprises winglesslint 8D (Wnt-8D) polypeptides for treating asthma, nervous system, psychological, alzheimer, cancer, cardiomyopathies, lung and kidney disorders; wound healing agents; tissue engineering |
| 09/18/2003 | US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents |
| 09/18/2003 | US20030175274 Polynucleotides codes for antibodies having amino acid sequences selected from complementary determining regions of variable peptides or single chain fragments, used as anticarcinogenic agents |
| 09/18/2003 | CA2482191A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | CA2481371A1 Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| 09/18/2003 | CA2479065A1 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 09/18/2003 | CA2479016A1 Quinazoline compounds useful in therapy |
| 09/18/2003 | CA2478931A1 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus |
| 09/18/2003 | CA2478921A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | CA2478897A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 09/18/2003 | CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity |
| 09/18/2003 | CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| 09/17/2003 | EP1344777A1 Imidazole derivatives, process for their preparation and their use |
| 09/17/2003 | EP1344064A2 Compositions and methods relating to prostate specific genes and proteins |
| 09/17/2003 | EP1343912A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 09/17/2003 | EP1343900A2 Oxidoreductases |
| 09/17/2003 | EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases |
| 09/17/2003 | EP1343817A2 Novel treatment |
| 09/17/2003 | EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 09/17/2003 | EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/17/2003 | EP1343778A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 09/17/2003 | EP1343775A2 Piperazine derivatives |
| 09/17/2003 | EP1343764A1 Urea and urethane derivatives as integrin inhibitors |
| 09/17/2003 | EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 09/17/2003 | EP1343751A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 09/17/2003 | EP1343544A2 Uses of a medical device having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 09/17/2003 | EP1343520A2 New therapeutic uses of smr1 peptides |
| 09/17/2003 | EP1343519A2 Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 09/17/2003 | EP1343517A2 Survical promoting ncam binding and ncam ligand biding compounds |
| 09/17/2003 | EP1343508A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis |
| 09/17/2003 | EP1343506A1 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 09/17/2003 | EP1343505A1 Cxcr3 antagonists |
| 09/17/2003 | EP1343492A2 Treatment of mucositis |
| 09/17/2003 | EP1314426A9 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 09/17/2003 | EP1224174B1 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 09/17/2003 | EP1200445B1 Thienopyranecarboxamide derivatives |
| 09/17/2003 | EP1192163B1 DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 09/17/2003 | EP1187627B1 Uses of h-trek-1 polypeptides and polynucleotides encoding them |
| 09/17/2003 | EP1123296B1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| 09/17/2003 | EP0996446B1 Novel substituted imidazole compounds |
| 09/17/2003 | EP0984777B1 Arylsubstituted piperazines useful in the treatement of benign prostatic hyperlasia |
| 09/17/2003 | EP0910566B1 Heterocyclic compounds and their preparation and use |
| 09/17/2003 | CN1443187A Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 09/17/2003 | CN1443184A 嘧啶衍生物 Pyrimidine derivatives |
| 09/17/2003 | CN1443178A (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl] -4-morpholibenzamide |
| 09/17/2003 | CN1443176A Valsartan salts |
| 09/17/2003 | CN1443170A Capsaicin receptor ligands |
| 09/17/2003 | CN1443164A Pyrrolidine derivatives as metalloprotease inhibitors |
| 09/17/2003 | CN1443163A Pyrrolidine-2-carboxylic acid hydrozide derivatives for use as metalloprotease inhibitors |
| 09/17/2003 | CN1443162A New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation |
| 09/17/2003 | CN1443065A Pharmaceutical composition improved in peroral absorbability |
| 09/17/2003 | CN1442168A Chinese medicine for supplementing kidney and fortifying spleen |
| 09/17/2003 | CN1442165A Chinese medicine for treating chronic nephritis and its preparation method |
| 09/17/2003 | CN1442146A New pharmaceutical of cactus total flavone and its preparation method |
| 09/17/2003 | CN1442141A Ferulic acid salt injection agent |
| 09/17/2003 | CN1442139A Medicinal composition for treating inflammation |
| 09/17/2003 | CN1121390C Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 09/16/2003 | US6620919 Lipoxin compounds and their use in treating cell proliferative disorders |
| 09/16/2003 | US6620845 For therapy and prophylaxis of neurological diseases |
| 09/16/2003 | US6620840 Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 09/16/2003 | US6620820 Inhibitors of bone reabsorption and antagonists of vitronectin receptors |
| 09/16/2003 | US6620806 Estrogen agonist/antagonist to prevente myocardial infarction or stroke, maintaining or improving vascular reactivity, treat renal failure, peripheral arterial occlusive disease, coronary artery disease, or raynaud's phenomenon |
| 09/16/2003 | US6620789 Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs |
| 09/16/2003 | US6620782 compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or |
| 09/16/2003 | CA2249009C Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
| 09/16/2003 | CA2182183C Treatment of ovarian estrogen dependent conditions |
| 09/16/2003 | CA2019404C 11 beta-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents |
| 09/12/2003 | WO2003074654A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 09/12/2003 | WO2003074516A1 Phthalimide carboxylic acid derivatives |
| 09/12/2003 | WO2003074483A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| 09/12/2003 | WO2003074008A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003073987A2 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 09/12/2003 | WO2003073986A2 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | WO2003073841A2 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
| 09/12/2003 | WO2003051333B1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/12/2003 | WO2003034987A3 Androgen receptor modulators and methods of use thereof |
| 09/12/2003 | WO2003032969A3 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 09/12/2003 | WO2002080979A3 Conjugate of hydroxyalkyl starch and an active agent |
| 09/12/2003 | WO2002032961A8 Novel polypeptides and nucleic acids encoding same |
| 09/12/2003 | WO2002009683A3 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 09/12/2003 | WO2001095785A3 Modulation of immune response and methods based thereon |
| 09/12/2003 | CA2481307A1 Phthalimide carboxylic acid derivatives |
| 09/12/2003 | CA2477715A1 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
| 09/12/2003 | CA2477449A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | CA2477423A1 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 09/12/2003 | CA2477119A1 Compounds that modulate the activity of ptp-1b and tc-ptp |
| 09/12/2003 | CA2455447A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 09/11/2003 | WO2003074500A2 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors |
| 09/11/2003 | WO2003074449A2 Multi-substitued selective androgen receptor modulators and methods of use thereof |
| 09/11/2003 | US20030171556 Diagnosis and therapeutic treatment of Alzheimer's Disease; drug screening |
| 09/11/2003 | US20030171541 Selective binding agents, vectors, host cells, and methods for producing GPCR polypeptides; diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with GPCR polypeptides |
| 09/11/2003 | US20030171422 Aldose reductase inhibitors; antidiabetic agents |
| 09/11/2003 | US20030171404 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 09/11/2003 | US20030171394 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/11/2003 | US20030171384 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 09/11/2003 | US20030171362 Amino-tetralin derivatives as muscarinic receptor antagonists |
| 09/11/2003 | US20030171361 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis |